History | Pembrolizumab for adjuvant treatment of completely resected stage 3 melanoma | Guidance | NICE

History

Documents created during the development process.

Expected publication

Equality Impact Assessment (Guidance development) (PDF 144 KB)

Published:

02 February 2022
Register of interests (PDF 122 KB)

Published:

02 February 2022

Final draft guidance

Final draft guidance
Final appraisal document (PDF 217 KB)

Published:

17 December 2021
Committee papers (PDF 5.97 MB)

Published:

17 December 2021
Public committee slides (PDF 1.51 MB)

Published:

17 December 2021

Invitation to participate

Final scope (PDF 174 KB)

Published:

07 July 2021
Final stakeholder list (PDF 187 KB)

Published:

07 July 2021

Final draft guidance: TA553

Final appraisal document - TA553 (PDF 290 KB)

Published:

20 November 2018
Committee papers - TA553 (PDF 15.28 MB)

Published:

19 November 2018
Public committee slides - TA553 (PDF 1.13 MB)

Published:

19 November 2018
Final appraisal document - managed access agreement - TA553 (PDF 547 KB)

Published:

26 November 2018
Final appraisal document - equality impact assessment - TA553 (PDF 222 KB)

Published:

19 December 2018
Committee papers - register of interests - TA553 (PDF 125 KB)

Published:

03 April 2019

Invitation to participate

Final scope - TA553 (PDF 224 KB)

Published:

16 April 2018
Final stakeholder list - TA553 (PDF 260 KB)

Published:

16 April 2018
NICE's response to comments on the draft scope and provisional stakeholder list - TA553 (PDF 206 KB)

Published:

16 April 2018
Equality impact assessment (Scoping) - TA553 (PDF 173 KB)

Published:

16 April 2018